The human spermatozoon – a stripped down but refined machine
© BioMed Central Ltd 2009
Published: 7 August 2009
Skip to main content
© BioMed Central Ltd 2009
Published: 7 August 2009
A recent paper in BMC Developmental Biology describes the development of the annulus of the mouse sperm cell, but much remains to be learnt about sperm cells despite their importance in human fertility.
In a world in which population growth and its subsequent control seem to be critical problems, it is counterintuitive to think that one in six couples are subfertile (still trying for a child after over 1 year of unprotected intercourse). In fact, approximately 80 million couples throughout the world are subfertile . What is perhaps more surprising is that male infertility accounts for at least 50% of these cases and that sperm dysfunction (sperm being present in the ejaculate but lacking 'normal' function) is the single most common cause, affecting approximately one in 20 men. This is a high proportion of the population compared with other prevalent diseases; male subfertility is thus a very significant global problem and, most worryingly, reports suggest that its prevalence is increasing.
A recent report by Guan and colleagues in BMC Developmental Biology  describes the development of a specific but relatively poorly studied structure, the annulus, in the formation of the mature spermatozoon. The annulus is an electron dense ring structure at the junction of the mid piece and principal piece. Its function is not clearly established but it may constitute a diffusion barrier between the two compartments and/or facilitate mitochondria migration and alignment along the axoneme. This study adds to what is a remarkably small amount of knowledge about the human sperm cell. Here, we review what we know about this highly specialized cell, the spermatozoon, and what treatments are available for men with sperm dysfunction.
Unfortunately, no treatments are available for sperm dysfunction except for those that simply bring the sperm closer to the egg. Despite the claims of a number of authors, there is no drug a man can take to improve sperm function. The only realistic treatment option for the man is assisted conception (one of the treatments that are collectively termed assisted reproductive technology or ART), which in the majority of cases consists of in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI). IVF is used if there are sufficient sperm available to add to eggs in culture (about 500,000 sperm at about 50,000 per egg). ICSI, which is by far the more common technique, is generally used when only a few sperm (<2–3 × 106) are seen in the ejaculate and they are perceived to be too weak or abnormal to penetrate the outer layers of an egg. A single spermatozoon is then selected by the embryologist and injected directly into the cytoplasm of the egg. Both these techniques are expensive (an average of about 7,000 per cycle in the UK), they are invasive, they have limited success (in the overwhelming majority of European Union countries, fewer than 25% of cycles started produce a birth ), they carry significant risks and they are not widely available. However, the number of ART cycles is increasing in all areas of the world and shows no signs of leveling off, probably because there are no alternative treatments and also because couples are leaving it later to try for children and ignoring the negative consequences of age on gamete quality in men and women.
In addition, a bedrock tool of understanding – knockout mice – has limited use in this context because (i) there is significant redundancy in the reproductive process, (ii) the pathology of knockouts, although similar to that seen in men with sperm dysfunction, is often not the same, and (iii) fertilization in humans has several very specific differences from that in mice. Consequently, successful examples of identifying gene defects in subfertile men by screening for genes knocked out in mice are rare. Usually no mutations in a gene of interest are found. For example, knockout mice lacking the Csnk2a2 gene (which encodes casein kinase IIa) have round-headed sperm similar to those seen in subfertile men with globozoospermia, but when six such men were tested for mutations in the human homolog of the gene, no mutations were found . Thus, alternative strategies are required. Recently, breakthrough results using other techniques have appeared in three areas: the composition of the spermatozoon, the packaging of sperm DNA and the chemotaxis that leads the sperm to the egg.
With no physiologically active transcription and translation, spermatozoa are ideal cells to study from a proteomic perspective – a true proteome can be established . The first indication of the complete sperm toolkit – the human sperm proteome – is now appearing . This includes some surprising findings, such as that sperm have a complete proteasome (used for degrading proteins for reuse), which is at odds with the idea of a cell type that does not require protein turnover. Data will probably be available on specific regions of the cell, such as tail proteins, membrane proteins and nuclear complexes, which together will allow a comprehensive first draft of the human sperm proteome. Comparing this with the proteomes of sperm from other species will help to answer fundamental questions, such as what basic machinery is necessary to make a functionally mature male gamete.
Proteomics also provides the opportunity to examine key dynamic processes involving post-translational protein modifications, about which we know almost nothing; for example, the development of fertilizing capacity (capacitation). Key kinases are only just being identified, and the first details of the identity and dynamics of proteins phosphorylated during human sperm capacitation have now emerged . Such studies will not be confined to phosphorylation, as the first, rough draft of the human sperm S-nitroso proteome is now available, which shows that over 240 proteins undergo post-translational modification (S-nitrosylation) in response to stimulation with nitric oxide, which enhances sperm motility .
Proteomic studies such as these [5–8] will allow a comprehensive and unbiased comparison between the normal spermatozoon and abnormal or dysfunctional cells, providing insights into critical aspects of sperm function and dysfunction. However, current case reports are limited by rather crude and unconvincing clinical diagnosis, for example 'poor' motility (which encompasses many causes), combined with unsophisticated proteomics and bioinformatics. Therefore, only a glimpse of the richness of the data has yet been revealed. With refined diagnosis and more sophisticated proteomics, such as quantitative labeling, our understanding will increase substantially.
The chromatin packaging in the mature spermatozoon is very different from that of somatic cells – it is very tightly packed, and the DNA is resistant to nucleases and sonication and cannot repair itself. The DNA is arranged into a toroid structure in which protamines account for at least 90% of the chromatin and histones for about 10%. Abnormalities in packaging, such as abnormal ratios between protamines 1 and 2, have been known for some time to have adverse reproductive consequences, such as reduced success at ART. However, surprisingly little is known about the histone fraction, which was previously presumed to be a 'leftover' from remodeling during spermiogenesis (the last stages of spermatogenesis when the cell is transformed from a round haploid cell to a motile cell). Recent data have changed our perception and suggested a bias in gene localization, with the histone-containing regions containing significantly more genes encoding proteins involved in embryogenesis than other regions . In addition, the histones are susceptible to a myriad of potential epigenetic changes through the histone code, the normality of which could easily be disturbed in dysfunctional cells. This is a level of complexity in the sperm cell that has not yet been fully appreciated.
Of critical importance to men with sperm dysfunction is the unambiguous relationship between poor-quality sperm and high levels of DNA damage in the cells. This has minimal relevance for natural conception as damaged cells are unable to fertilize, but with ICSI cells with high levels of DNA damage are often the only ones available and are thus used for injection. Clinical data from many ART programs using a variety of DNA-damage assays show a strong negative correlation between DNA damage in the sperm and rates of embryo development and implantation and, importantly, a positive correlation with levels of miscarriage . However, the longer term consequences of using damaged cells, such as the health of offspring, are unknown. Data from mice suggest that caution is needed, as using DNA-damaged sperm for ICSI was associated with pathological changes in the resultant adult offspring, such as changes in behavior, higher incidence of cancer and premature aging .
We are only at the beginning of our understanding of sperm chromatin and DNA and, when there is damage, we do not know the point in the lifecycle of the cell at which the damage originates, its causes (for example whether it is oxidative in nature) or the nature of the damage (for example, single- and/or double-strand breaks and/or DNA crosslinking). Other basic questions remain unanswered. Does the origin and nature of the damage suggest less or more severe consequences? Can the egg repair the damage and, if so, is there a threshold of damage above which it can no longer do so? This is an unusual field in which the clinical data are relatively clear and consistent but have yet to be accompanied with high quality scientific studies.
A fascinating aspect of internal fertilization in humans is that sperm operate in a highly complex, mucus-based environment, with different viscoelastic properties and fluid mechanics from those of the simple media that are universally used to study motility. For example, sperm preferentially swim along surfaces and thus might crawl, rather than swim, up the female reproductive tract. As a result, experiments modeling and examining sperm behavior in these physiologically relevant environments are essential for obtaining an accurate analysis, as recently demonstrated by Smith and colleagues .
In summary, there is an urgent need to develop a more detailed understanding of the physiological, biochemical and molecular functioning of the human sperm cell. We can use this knowledge as a platform to improve the diagnosis of male infertility with, for example, robust biomarkers and the development of non-ART-based therapies. The tools at our disposal have never been more accessible, powerful and sophisticated, so, if they are used wisely, it is likely that rapid progress will be made in the very near future. Perhaps then a structure such as the annulus – which has been known for over 100 years – will reveal its secrets.
Work in the authors' laboratories is sponsored by NHS Tayside, Wellcome Trust, TENOVUS (Scotland), University of Dundee, British Council and Scottish Enterprise. The authors thank all patients and donors for providing samples for the Reproductive and Developmental Biology research program in Dundee.